• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The Fibrates Story - A Tepid End to a PROMINENT Drug.

作者信息

Virani Salim S

机构信息

From the Health Policy, Quality, and Informatics Program, Health Services Research and Development Center for Innovations, and the Section of Cardiology, Michael E. DeBakey Veterans Affairs Medical Center, and the Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine - both in Houston.

出版信息

N Engl J Med. 2022 Nov 24;387(21):1991-1992. doi: 10.1056/NEJMe2213208. Epub 2022 Nov 5.

DOI:10.1056/NEJMe2213208
PMID:36342123
Abstract
摘要

相似文献

1
The Fibrates Story - A Tepid End to a PROMINENT Drug.贝特类药物的故事——一种著名药物的平淡结局。
N Engl J Med. 2022 Nov 24;387(21):1991-1992. doi: 10.1056/NEJMe2213208. Epub 2022 Nov 5.
2
[Fibrates, clinical use and their effects].[贝特类药物、临床应用及其效果]
Nihon Rinsho. 2011 Jan;69 Suppl 1:614-20.
3
Fibrates and cardiorenal outcomes.贝特类药物与心肾结局
J Am Coll Cardiol. 2012 Nov 13;60(20):2072-3. doi: 10.1016/j.jacc.2012.06.058. Epub 2012 Oct 17.
4
[Fibrates].[贝特类药物]
Nihon Rinsho. 2013 Sep;71(9):1643-8.
5
Evidence for use of fibrates in diabetic dyslipidemia: are we looking hard enough?贝特类药物用于糖尿病血脂异常的证据：我们找得够仔细吗？
Curr Opin Lipidol. 2011 Feb;22(1):76-7. doi: 10.1097/MOL.0b013e328342b0e9.
6
[Part I. Fibrates in primary and secondary prevention].第一部分：贝特类药物在一级和二级预防中的应用
Clin Investig Arterioscler. 2016 Jul;28 Suppl 3:3-10. doi: 10.1016/S0214-9168(16)30083-3.
7
[Clinical evidence of statins and fibrates in the management of dyslipidemia in Japan].[他汀类药物和贝特类药物在日本血脂异常管理中的临床证据]
Nihon Rinsho. 2011 Jan;69 Suppl 1:621-5.
8
Analysis of the Cochrane Review: Fibrates for secondary prevention of cardiovascular disease and stroke.考克兰系统评价分析：贝特类药物用于心血管疾病和中风的二级预防
Rev Port Cardiol. 2017 Jan;36(1):55-58. doi: 10.1016/j.repc.2016.05.008. Epub 2016 Dec 13.
9
[Fibrates: their prescription must be restricted].[贝特类药物：必须限制其处方使用]
Rev Prat. 2015 Dec;65(10):1243-4.
10
Comparison of the efficacy of fibrates on hypertriglyceridemic phenotypes with different genetic and clinical characteristics.比较不同遗传和临床特征的高甘油三酯血症表型中纤维酸类药物的疗效。
Pharmacogenet Genomics. 2010 Dec;20(12):742-7. doi: 10.1097/FPC.0b013e328340095e.

引用本文的文献

1
Effect of Fibrates on Lipoprotein-associated Phospholipase A2 Mass and Activity: A Systematic Review and Meta-analysis of Controlled Clinical Trials.贝特类药物对脂蛋白相关磷脂酶A2含量及活性的影响：对照临床试验的系统评价和荟萃分析
Curr Pharm Des. 2025;31(15):1205-1212. doi: 10.2174/0113816128345231240925095400.
2
Mechanisms of hepatic and renal injury in lipid metabolism disorders in metabolic syndrome.代谢综合征中脂质代谢紊乱导致的肝肾功能损伤机制。
Int J Biol Sci. 2024 Sep 9;20(12):4783-4798. doi: 10.7150/ijbs.100394. eCollection 2024.
3
Triglyceride-rich lipoproteins and cardiovascular diseases.
富含甘油三酯的脂蛋白与心血管疾病。
Front Endocrinol (Lausanne). 2024 May 31;15:1409653. doi: 10.3389/fendo.2024.1409653. eCollection 2024.
4
Atherosclerosis Residual Lipid Risk-Overview of Existing and Future Pharmacotherapies.动脉粥样硬化残留脂质风险——现有及未来药物治疗概述
J Cardiovasc Dev Dis. 2024 Apr 21;11(4):126. doi: 10.3390/jcdd11040126.
5
Fixed Combination for the Treatment of Dyslipidaemia.固定剂量复方制剂治疗血脂异常。
Curr Atheroscler Rep. 2023 Oct;25(10):691-699. doi: 10.1007/s11883-023-01142-x. Epub 2023 Sep 16.
6
Mitogen-Activated Protein Kinase and Nuclear Hormone Receptor Crosstalk in Cancer Immunotherapy.丝裂原活化蛋白激酶与核激素受体在癌症免疫治疗中的相互作用
Int J Mol Sci. 2023 Sep 4;24(17):13661. doi: 10.3390/ijms241713661.
7
Triglycerides and risk of cardiovascular events in statin-treated patients with newly diagnosed type 2 diabetes: a Danish cohort study.新诊断为 2 型糖尿病且正在接受他汀类药物治疗的患者的甘油三酯与心血管事件风险：一项丹麦队列研究。
Cardiovasc Diabetol. 2023 Jul 26;22(1):187. doi: 10.1186/s12933-023-01921-5.
8
The Emerging Role of Icosapent Ethyl in Patients with Cardiovascular Disease: Mechanistic Insights and Future Applications.二十碳五烯酸乙酯在心血管疾病患者中的新作用：机制见解与未来应用
J Clin Med. 2023 May 30;12(11):3758. doi: 10.3390/jcm12113758.
9
Focus on the Prevention of Acute Limb Ischemia: Centrality of the General Practitioner from the Point of View of the Internist.关注急性肢体缺血的预防：从内科医生角度看全科医生的核心地位
J Clin Med. 2023 May 24;12(11):3652. doi: 10.3390/jcm12113652.
10
Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis.新型选择性过氧化物酶体增殖物激活受体α（PPARα）调节剂培马贝特用于治疗血脂异常、非酒精性脂肪性肝病（NAFLD）和动脉粥样硬化
Metabolites. 2023 May 2;13(5):626. doi: 10.3390/metabo13050626.